A Phase 2a, open-label, two-part study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) on airway inflammation in patients with chronic obstructive pulmonary disease (COPD)

Project: Research project

Project Details

StatusActive
Effective start/end date6/6/226/5/27

Funding

  • Sanofi US Services Inc: $11,000.00